LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome by Diana E. Ramirez-Ardila, Kirsten Ruigrok-Ritstier, Jean C. Helmijr, Maxime P. Look, Steven van Laere, Luc Dirix, Els M.J.J. Berns, Maurice P.H.M. Jansen

Get full text

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels by Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris

Get full text

<i>TP53</i> Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer by Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, Corine M. Beaufort, Jean C. Helmijr, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Patricia C. Ewing-Graham, Ramon Smolders, Helena C. van Doorn, Ingrid A. Boere, Els M. J. J. Berns, Jozien Helleman, Maurice P. H. M. Jansen

Get full text

The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study by Aad van der Lugt, Dik C van Gent, Gerda M Verduijn, Marta E Capala, Nienke D Sijtsema, Iris Lauwers, Juan A Hernandez Tamames, Wilma D Heemsbergen, Aniel Sewnaik, Jose A Hardillo, Hetty Mast, Yvette van Norden, Maurice P H M Jansen, Mischa S Hoogeman, Bianca Mostert, Steven F Petit

Get full text

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer by Erik J. vanHelden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. vanEs, Sandra A. Radema, Carla M. L. vanHerpen, Derk Jan A. deGroot, Elisabeth G. E. deVries, Maurice P. H. M. Jansen, Stefan Sleijfer, Henk M. W. Verheul

Get full text